Intact Investment Management Inc. Lowers Holdings in AbbVie Inc. $ABBV

Key Points

• Intact Investment Management cut its AbbVie stake by 16.5% in Q4, selling 17,410 shares and finishing the quarter with 87,790 shares valued at about $20.06 million.
• AbbVie beat Q1 estimates and raised its 2026 outlook, with Skyrizi and Rinvoq offsetting Humira declines and prompting multiple analyst upgrades and higher price targets.
• Large insider selling (e.g., SVP sold 5,230 shares; EVP sold 22,381 shares) and recent pipeline trimming have pressured sentiment, even as AbbVie pays a $1.73 quarterly dividend (3.3% yield) and trades in a one‑year range of $176.57–$244.81.

Intact Investment Management Inc. decreased its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 16.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 87,790 shares of the company's stock after selling 17,410 shares during the quarter. Intact Investment Management Inc.'s holdings in AbbVie were worth $20,059,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Mcdonald Partners LLC increased its holdings in shares of AbbVie by 1.9% in the 4th quarter. Mcdonald Partners LLC now owns 19,967 shares of the company's stock worth $4,562,000 after purchasing an additional 378 shares in the last quarter. Core Alternative Capital increased its holdings in shares of AbbVie by 661.5% in the 4th quarter. Core Alternative Capital now owns 2,155 shares of the company's stock worth $492,000 after purchasing an additional 1,872 shares in the last quarter. AlphaStar Capital Management LLC increased its holdings in shares of AbbVie by 4.3% in the 4th quarter. AlphaStar Capital Management LLC now owns 25,257 shares of the company's stock worth $5,771,000 after purchasing an additional 1,033 shares in the last quarter. Woodard & Co. Asset Management Group Inc. ADV increased its holdings in shares of AbbVie by 2.0% in the 4th quarter. Woodard & Co. Asset Management Group Inc. ADV now owns 8,340 shares of the company's stock worth $1,906,000 after purchasing an additional 166 shares in the last quarter. Finally, VELA Investment Management LLC increased its holdings in shares of AbbVie by 37.3% in the 4th quarter. VELA Investment Management LLC now owns 7,445 shares of the company's stock worth $1,701,000 after purchasing an additional 2,022 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company's stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 earnings beat and guidance lift — AbbVie topped Q1 estimates, raised its 2026 outlook and said immunology drugs (Skyrizi, Rinvoq) are offsetting Humira declines. This is the core positive catalyst supporting analyst upgrades. Seeking Alpha: AbbVie hikes 2026 outlook BioSpace: AbbVie tops Q1, raises outlook
• Positive Sentiment: Sell‑side upgrades and higher price targets — Multiple firms raised ratings/targets after the results (Morgan Stanley to $278, Canaccord to $265, Guggenheim reaffirm/ $249 PT, Bank of America upgraded to Buy/$234, Cantor reiterated Overweight/$240). These lifts signal renewed analyst conviction in AbbVie’s post‑Humira pivot. Benzinga: analyst moves InsiderMonkey: BofA upgrade
• Positive Sentiment: Skyrizi competitive defense — AbbVie outlined how Skyrizi will respond to new J&J plaque‑psoriasis rival Icotyde, reinforcing confidence in market share retention for a key growth driver. FiercePharma: Skyrizi defense
• Neutral Sentiment: Corporate R&D/community engagement — AbbVie awarded the AbbVie Biotech Innovators prize to RIME Therapeutics (Quebec), signalling long‑term commitment to immunology innovation, but limited near‑term financial impact. GlobeNewswire: RIME award
• Negative Sentiment: Investors remain jittery despite the beat — WSJ coverage and market commentary highlight that, while results were strong, concerns over Humira erosion, execution risk on acquisitions/pipeline strategy, and valuation keep sentiment cautious and likely drove selling pressure. YouTube/WSJ: Investors still worried
• Negative Sentiment: Pipeline trimming and insider selling — The company discontinued a cancer candidate (noted in Q1 coverage) and recent disclosures show insiders sold shares, which can weigh on near‑term sentiment. BioSpace: discontinued candidate
• Negative Sentiment: Small analyst estimate cuts and mixed institutional flows — Erste trimmed FY2026/27 EPS modestly; recent large institutional portfolio shifts (some big sellers) add uncertainty to demand. These are headwinds for the stock near term. MarketBeat: analyst/flows summary

Insider Buying and Selling at AbbVie

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the business's stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares of the company's stock, valued at approximately $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the business's stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the sale, the executive vice president directly owned 38,137 shares of the company's stock, valued at $8,771,510. This represents a 36.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 0.06% of the company's stock.

AbbVie Price Performance

Shares of ABBV opened at $206.63 on Monday. AbbVie Inc. has a one year low of $176.57 and a one year high of $244.81. The firm has a market capitalization of $365.36 billion, a P/E ratio of 101.79, a PEG ratio of 0.71 and a beta of 0.32. The business has a fifty day moving average of $214.55 and a 200 day moving average of $221.49.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 911.57% and a net margin of 5.79%.The company had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. During the same quarter in the previous year, the company posted $2.46 earnings per share. AbbVie's revenue was up 12.4% compared to the same quarter last year. Analysts expect that AbbVie Inc. will post 14.29 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.3%. AbbVie's payout ratio is presently 340.89%.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Barclays assumed coverage on AbbVie in a report on Thursday, February 19th. They issued an "overweight" rating and a $275.00 target price for the company. Morgan Stanley lifted their target price on AbbVie from $270.00 to $278.00 and gave the stock an "overweight" rating in a report on Thursday. DZ Bank raised AbbVie from a "hold" rating to a "strong-buy" rating in a report on Thursday. Weiss Ratings reissued a "hold (c)" rating on shares of AbbVie in a report on Wednesday, January 21st. Finally, UBS Group reduced their target price on AbbVie from $240.00 to $230.00 and set a "neutral" rating for the company in a report on Thursday, February 5th. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have issued a Hold rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $252.90.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.